Volpara Health Technologies Ltd’s (ASX:VHT) early breast cancer detection solution will be trialled in the United Kingdom for possible inclusion in the NHS Breast Screening Program.
A VolparaDensity™ software implementation trial will take place in the Greater Manchester, East Cheshire and East Lancashire regions.
It is the next step towards a potential further rollout of density and risk-based screening across England.
Breast screening program one of world’s largest
England’s breast screening program is one of world’s largest, imaging 2 million women each year.
Volpara was selected following its use in the Predicting Risk of Cancer at Screening (PROCAS) I study, which recruited participants over 66 months from the Greater Manchester Breast Screening Program.
The trial is part of the PROCAS II Program Grant, ‘Providing breast cancer risk information as part of national breast cancer screening program: building an evidence base on benefits and harms to inform a decision to implement’.
Funding from National Institute for Health Research
The grant will be run from the Manchester University NHS Foundation Trust from funding by the National Institute for Health Research, which aims to improve the health and economy of the U.K.
In the trial, all consenting women screened for breast cancer in the three regions will receive breast cancer risk information.
This will be based on a risk assessment incorporating mammographic density estimated by VolparaDensity™ software.
The trial is expected to be deployed across six sites, covering more than 8,000 women, and will run for two years with an initial consultation period.
READ: Volpara Health Technologies delivers record sales for breast cancer detection solutions
This follows Volpara delivering record monthly sales performance in January for its early breast cancer detection solutions.
The New Zealand-based company added total contract value of NZ$1.2 million in January 2018, more than 400% higher than the same month in 2017.